PL423193A1 - Composition of alcohol extracts and its applications - Google Patents

Composition of alcohol extracts and its applications

Info

Publication number
PL423193A1
PL423193A1 PL423193A PL42319317A PL423193A1 PL 423193 A1 PL423193 A1 PL 423193A1 PL 423193 A PL423193 A PL 423193A PL 42319317 A PL42319317 A PL 42319317A PL 423193 A1 PL423193 A1 PL 423193A1
Authority
PL
Poland
Prior art keywords
composition
alcohol extracts
subject
alcohol
modulator
Prior art date
Application number
PL423193A
Other languages
Polish (pl)
Other versions
PL236893B1 (en
Inventor
Agata Maria Gaweł
Damian Kamil Gaweł
Marlena Godlewska
Original Assignee
Centrum Medyczne Ksztalcenia Podyplomowego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrum Medyczne Ksztalcenia Podyplomowego filed Critical Centrum Medyczne Ksztalcenia Podyplomowego
Priority to PL423193A priority Critical patent/PL236893B1/en
Publication of PL423193A1 publication Critical patent/PL423193A1/en
Publication of PL236893B1 publication Critical patent/PL236893B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja ekstraktów alkoholowych otrzymanych z wybranych roślin leczniczych wybranych co najmniej z jednego rodzaju spośród Prunus sp., Crataegus sp., Sorbus sp., Euonymus sp., wybranych korzystnie spośród gatunków Prunus spinosa, Crataegus monogyna, Sorbus aucuparia, Euonymus europaeus. Ekstrakty alkoholowe otrzymane są z owoców wybranych roślin, a stosunek objętościowy ekstraktów alkoholowych w kompozycji odpowiednio wynosi 1:1:1:1. Alkohol alifatyczny do ekstrakcji wybrany jest spośród metanolu lub etanolu. Przedmiotem zgłoszenia jest także zastosowanie przedmiotowej kompozycji jako modulatora lekooporności w komórkach i/lub modulatora potencjału migracyjnego, adhezji i proliferacji komórek nowotworowych. Dodatkowo zgłoszenia dotyczy zastosowania kompozycji jako środka leczniczego stosowanego razem z chemioterapeutykami do wspomagania terapii nowotworowej, przy czym kompozycję tę podaje się korzystnie przed podaniem leku.The subject of the application is a composition of alcohol extracts obtained from selected medicinal plants selected from at least one type from among Prunus sp., Crataegus sp., Sorbus sp., Euonymus sp., Preferably selected from the species Prunus spinosa, Crataegus monogyna, Sorbus aucuparia, Euonymus europaeus. Alcohol extracts are obtained from the fruits of selected plants, and the volume ratio of alcohol extracts in the composition is 1: 1: 1: 1, respectively. The aliphatic alcohol for extraction is selected from methanol or ethanol. The subject of the application is also the use of the subject composition as a modulator of drug resistance in cells and / or a modulator of migration potential, adhesion and proliferation of cancer cells. In addition, applications relate to the use of the composition as a medicament used together with chemotherapeutic agents to promote cancer therapy, the composition preferably being administered prior to drug administration.

PL423193A 2017-10-18 2017-10-18 Composition of alcohol extracts and its applications PL236893B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL423193A PL236893B1 (en) 2017-10-18 2017-10-18 Composition of alcohol extracts and its applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL423193A PL236893B1 (en) 2017-10-18 2017-10-18 Composition of alcohol extracts and its applications

Publications (2)

Publication Number Publication Date
PL423193A1 true PL423193A1 (en) 2019-04-23
PL236893B1 PL236893B1 (en) 2021-02-22

Family

ID=66167839

Family Applications (1)

Application Number Title Priority Date Filing Date
PL423193A PL236893B1 (en) 2017-10-18 2017-10-18 Composition of alcohol extracts and its applications

Country Status (1)

Country Link
PL (1) PL236893B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010046028A (en) * 1999-11-10 2001-06-05 구광시 Composition for treatment of tumor containing extract of Euonymus alatus
CN103417668A (en) * 2013-07-29 2013-12-04 辽宁大学 Application of sorbus sibirica fruit extract to preparation of drugs or health care products with HeLa cell resistance
WO2016157233A1 (en) * 2015-04-01 2016-10-06 Istituto Superiore di Sanità Prunus spinosa extracts with anti-tumor activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010046028A (en) * 1999-11-10 2001-06-05 구광시 Composition for treatment of tumor containing extract of Euonymus alatus
CN103417668A (en) * 2013-07-29 2013-12-04 辽宁大学 Application of sorbus sibirica fruit extract to preparation of drugs or health care products with HeLa cell resistance
WO2016157233A1 (en) * 2015-04-01 2016-10-06 Istituto Superiore di Sanità Prunus spinosa extracts with anti-tumor activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARZU TURKER, ARZU BIRINCI YILDIRIM, FATMA PEHLIVAN KARAKAS, TURKEY ANTIBACTERIAL AND ANTITUMOR ACTIVITIES OF SOME WILD FRUITS GROWN IN TURKEY, April 2014 (2014-04-01) *
ARZU TURKER, ARZU BIRINCI YILDIRIM, FATMA PEHLIVAN KARAKAS, TURKEYANTIBACTERIAL AND ANTITUMOR ACTIVITIES OF SOME WILD FRUITS GROWN IN TURKEY, April 2014 (2014-04-01) *

Also Published As

Publication number Publication date
PL236893B1 (en) 2021-02-22

Similar Documents

Publication Publication Date Title
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
BR112015026247A8 (en) compound in combination with a cytidine analogue, pharmaceutical composition comprising them, use thereof and kit
EA202091318A1 (en) A PREPARATION CONTAINING GROUP B ADENOVIRUS
MX2022002946A (en) Cdk inhibitors and their use as pharmaceuticals.
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
CO2021013677A2 (en) Process for the manufacture of stable bacterial extracts and their use as drugs
MX2019009952A (en) Low-viscosity, high-concentration evolocumab formulations and methods of making the same.
PL423193A1 (en) Composition of alcohol extracts and its applications
AR112448A1 (en) SUBSTITUTED XANTHINE DERIVATIVES
PE20130782A1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF PARACETAMOL AND THE PROCESS FOR THE PREPARATION OF THE SAME
NZ718802A (en) Icotinib-containing topical skin pharmaceutical composition and use thereof
CL2022003426A1 (en) Levilimab Aqueous Pharmaceutical Composition and Its Use
BR112015028302A2 (en) nicotine tablet formulation
EA201992844A1 (en) NEW ORAL COMPOSITIONS BASED ON BELINOSTAT
AU2016101708A4 (en) The use of Machilus macrantha for the treatment of arthritis and wound healing
MX2018015759A (en) Vortioxetine dosing regimes for fast onset of antidepressant effect.
EA202190269A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A CHEWING TABLET OF DIOSMINE OR FLAVONOID FRACTION
AR120453A1 (en) COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR THE TREATMENT OF CANCER
EA202191570A1 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTIC DRUGS, METHODS OF THEIR APPLICATION AND OBTAINING
UA135187U (en) PHARMACEUTICAL COMPOSITION OF MULTI-DIRECTIVE ACTION IN THE FORM OF DENTAL GEL
ES2540457A1 (en) Procedure for obtaining leaf extracts from corema album and its therapeutic application (Machine-translation by Google Translate, not legally binding)
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
AR115724A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PEPTIDE
CO2019010902A1 (en) Liquid pharmaceutical composition containing dantrolene sodium
UA120529U (en) METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME